Live Breaking News & Updates on Tufiac haddad

Stay informed with the latest breaking news from Tufiac haddad on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Tufiac haddad and stay connected to the pulse of your community

AURKA Pathway Gains Ground as Targetable Option in Metastatic Breast Cancer

The AURKA inhibitor alisertib has emerged as an agent of particular note, demonstrating early signals of efficacy with a manageable safety profile for the treatment of patients with locally advanced or metastatic breast cancer whose disease is resistant to endocrine therapies.

Mayo-clinic-in-rochester , Minnesota , United-states , American , Karthikv-giridhar , Tufiac-haddad , Antonio-dassoro , Houj-aurora , Digital-health , Mayo-clinic-comprehensive-cancer-center , Mayo-clinic-college-of-medicine , American-society-of-clinical-oncology-annual-meeting

Alisertib Induces Early Signals of Efficacy in Endocrine-Resistant Breast Cancer

Alisertib as monotherapy and in combination with fulvestrant stands at the forefront of the clinical investigation of selective AURKA pathway inhibition in patients with endocrine-resistant advanced breast cancer, according to Tufia C. Haddad, MD.

Minnesota , United-states , Tufiac-haddad , Antonio-dassoro , Practice-innovation , Mayo-clinic-comprehensive-cancer-center , Antoniod-assoro , Puma-biotechnology , Alisertib- , Aurka-pathway- , Endocrine-resistant-advanced-breast-cancer

Telehealth's lasting impact on cancer care delivery

Telehealth's lasting impact on cancer care delivery
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Arizona , United-states , Florida , Minnesota , Tufiac-haddad , Joshuac-pritchett , Public-health-emergency-declaration , Mayo-clinic-health-system , Mayo-clinic-comprehensive-cancer-center , Mayo-clinic , Mayo-clinic-comprehensive-cancer

AI in Oncology: Current and Future Applications

AI has been used in oncology for years, but recent studies suggest AI could have many additional applications in cancer care.

Minnesota , United-states , New-york , Mayo-clinic-in-rochester , Tufiac-haddad , Olivier-elemento , Laurie-margolies , Drug-administration , National-comprehensive-cancer-network , Mayo-clinic , Mount-sinai , Weill-cornell-medicine

AI in Oncology: Current and Future Applications

AI has been used in oncology for years, but recent studies suggest AI could have many additional applications in cancer care.

Minnesota , United-states , Mayo-clinic-in-rochester , New-york , Tufiac-haddad , Olivier-elemento , Laurie-margolies , National-comprehensive-cancer-network , Drug-administration , Mayo-clinic , Mount-sinai , Weill-cornell-medicine

Growth of telehealth in cancer care continued after initial surge during COVID-19 pandemic

Growth of telehealth in cancer care continued after initial surge during COVID-19 pandemic
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Minnesota , United-states , Florida , Tufiac-haddad , Mayo-clinic-health-system , Mayo-clinic-comprehensive-cancer-center , Mayo-clinic-health ,

Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the results of the Phase II TBCRC041 randomized clinical trial of alisertib alone or in combination with fulvestrant in patients with endocrine-resistant advanced breast cancer have been published onlin...

United-states , Tufiac-haddad , Alanh-auerbach , Mayo-clinic-college-of-medicine , European-commission , Drug-administration , Nasdaq , Puma-biotechnology-inc , Translational-breast-cancer-research-consortium , Mayo-clinic-comprehensive-cancer-center , Puma-biotechnology